Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
Acute Myeloid Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)|Myelodysplastic Syndrome (MDS)
DRUG: CPX-351
Total Drug Plasma PK, The following parameters will be determined:Tmax, Cmax, AUC (0-last), AUC (0-inf), AUC (0-tau), Clast/位z, 位z, t1/2, Vss and CL, Pre-dose and up to Day 21 during first induction only
Serum Copper Levels, The following parameters will be determined:Tmax, Cmax, AUC (0-last), AUC (0-inf), AUC (0-tau), Clast/位z, 位z, t1/2, Vss and CL, Pre-dose and up to Day 21 during the first induction only, prior to every course the patient receives, early termination or end of study and 60 day post end of study.|Urine Sampling, Days 5-10 during the first induction only.|Efficacy and Safety, Efficacy and Safety are measured up until the end of study period, SAEs are measured up to 30 days from the end of study period.
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.